Xu Y - Search Results

1

ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect.

Li S, Ma W, Yang F, Xu Y, Xu B, Cai B. Li S, et al. Among authors: xu b, xu y. Curr Drug Targets. 2021;22(16):1832-1843. doi: 10.2174/1389450122666210319110320. Curr Drug Targets. 2021. PMID: 33745431 Review.

2

An individualized transcriptional signature to predict the epithelial-mesenchymal transition based on relative expression ordering.

Chen T, Zhao Z, Chen B, Wang Y, Yang F, Wang C, Dong Q, Liu Y, Liang H, Zhao W, Qi L, Xu Y, Gu Y. Chen T, et al. Among authors: xu y. Aging (Albany NY). 2020 Jul 8;12(13):13172-13186. doi: 10.18632/aging.103407. Epub 2020 Jul 8. Aging (Albany NY). 2020. PMID: 32639951 Free PMC article.

3

The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia.

Xu Y, Fang H, Chen Y, Tang Y, Sun H, Kong Z, Yang F, Kirschner-Schwabe R, Zhu L, Toker A, Xiao N, Zhou BS, Li H. Xu Y, et al. iScience. 2022 Feb 7;25(3):103881. doi: 10.1016/j.isci.2022.103881. eCollection 2022 Mar 18. iScience. 2022. PMID: 35243242 Free PMC article.

4

Single-cell and Bulk Transcriptomic Analyses Reveal a Stemness and Circadian Rhythm Disturbance-related Signature Predicting Clinical Outcome and Immunotherapy Response in Hepatocellular Carcinoma.

Zhu X, Zhang Z, Zhang J, Xiao Y, Wang H, Wang M, Jiang M, Xu Y. Zhu X, et al. Among authors: xu y. Curr Gene Ther. 2024 Jun 5. doi: 10.2174/0115665232298240240529131358. Online ahead of print. Curr Gene Ther. 2024. PMID: 38847249

5

Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.

Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y. Chen T, et al. Among authors: xu y. Br J Cancer. 2022 Sep;127(5):916-926. doi: 10.1038/s41416-022-01836-0. Epub 2022 May 26. Br J Cancer. 2022. PMID: 35618786 Free PMC article.

6

Identification of Primary and Metastatic Lung Cancer-Related lncRNAs and Potential Targeted Drugs Based on ceRNA Network.

Dong S, Wu C, Song C, Qi B, Liu L, Xu Y. Dong S, et al. Among authors: xu y. Front Oncol. 2021 Feb 3;10:628930. doi: 10.3389/fonc.2020.628930. eCollection 2020. Front Oncol. 2021. PMID: 33614509 Free PMC article.

7

A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis.

Zhu X, Zhang Z, Xiao Y, Wang H, Zhang J, Wang M, Jiang M, Xu Y. Zhu X, et al. Among authors: xu y. Heliyon. 2024 Jul 30;10(15):e35404. doi: 10.1016/j.heliyon.2024.e35404. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170145 Free PMC article.

8

Identification of potential cancer-related pseudogenes in lung adenocarcinoma based on ceRNA hypothesis.

Wei Y, Chang Z, Wu C, Zhu Y, Li K, Xu Y. Wei Y, et al. Among authors: xu y. Oncotarget. 2017 Aug 4;8(35):59036-59047. doi: 10.18632/oncotarget.19933. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938616 Free PMC article.

9

Identification of cancer-related potential biomarkers based on lncRNA-pseudogene-mRNA competitive networks.

Wu C, Wei Y, Zhu Y, Li K, Zhu Y, Zhao Y, Chang Z, Xu Y. Wu C, et al. Among authors: xu y. FEBS Lett. 2018 Mar;592(6):973-986. doi: 10.1002/1873-3468.13011. FEBS Lett. 2018. PMID: 29453881 Free article.

10

Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions.

Zhao N, Liu Y, Chang Z, Li K, Zhang R, Zhou Y, Qiu F, Han X, Xu Y. Zhao N, et al. Among authors: xu y. PLoS One. 2015 Sep 24;10(9):e0139165. doi: 10.1371/journal.pone.0139165. eCollection 2015. PLoS One. 2015. PMID: 26402252 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72,396 results

Search Page

Filters